The Artificial Intelligence & Cancers Association and the commitment of its Administrators: Interview with Sophie Bouju, Medical Director of Operational Expertise – Janssen
For the Janssen laboratories, innovation means openness, collaboration and cooperation. To achieve this, the Janssen laboratories believe it is important to bring together the power of the public and private sectors in the ecosystem. Thanks to this collective commitment, it will be possible to improve and stimulate the world of healthcare.
Linking an early access program (EAP) to the National Health Data System (NHDS) in France and assessing its performances and potential biases
Representatives of the Artificial Intelligence & Cancers Association, the French National Cancer Institute and AstraZeneca were honored to present at ASCO 2024 the results of a first collaborative project demonstrating the proof-of-concept of matching early access data with data from the SNDS.
The Artificial Intelligence & Cancers Association and the commitment of its Administrators: Interview with Christian Puppinck, Patient Representative – French National Cancer Institute
In this third video about the French National Cancer Institute, you’ll meet Christian Puppinck, a patient representative who brings experience, advice and the point of view of patients who have lived through the painful experience of illness and death.
The Artificial Intelligence & Cancers Association and the commitment of its Administrators: Interview with Stéphanie Kervestin, Executive Officer – Health Industry Alliance for Research and Innovation (ARIIS)
For this second interview on ariis, we present Stéphanie Kervestin, Executive Officer, who will answer our three questions. You’ll find out why this partnership, from both the public and private sectors, are joining forces within the Association, and how this cross-sector collaboration is the key to innovations that benefit patients and citizens alike.
The Artificial Intelligence & Cancers Association and the commitment of its Administrators: Interview with Marc Bonneville, Scientific and Medical Director – Institut Merieux and Chairman of ARIIS
In this interview, find out how ARIIS contributed to the creation of the Association, which shares its philosophy of action, notably by strengthening dialogue between public and private sectors and facilitating their collaboration.
The Artificial Intelligence & Cancers Association and the commitment of its Administrators: Interview with Philippe-Jean Bousquet, Public Health Physician and Director of Observation, Data Science and Evaluation – French National Cancer Institute
Discover, in this second video on the Institute, that she expects a frank and constructive commitment from all players in this Association project, in order to set up data reuse projects in oncology to federate the ecosystem and provide access to new data sources.
10 cancer data reuse projects in oncology in 2 years
Since 2021, the Intelligence Artificial and Cancers Association has been working alongside health industry companies, the French National Cancer Institute and the Health Data Hub, transforming healthcare data into therapeutic and diagnostic innovations for cancer patients. To date, ten cancer data reuse projects, led by health industry companies on themes with strong health stakes, have […]
The Artificial Intelligence & Cancers Association and the commitment of its Administrators: Interview with Thierry Breton, General Manager of the French National Cancer Institute
In this eighth interview, you’ll find out why the Institute decided to get involved in this project, mobilizing public and private partnership to serve patients.
Optimizing care pathways for better patient care
The care pathway corresponds to comprehensive patient care: it covers the phases of prevention, diagnosis, treatment and follow-up, involving a multitude of healthcare professionals. Influenced by many factors (individual, territorial, etc.), these care paths are highly diverse, with varying degrees of efficiency, and are sometimes subject to delays or disruptions, resulting in lost opportunity for […]
Better monitoring of “early access” patients
The French National Authority for Health defines early access as a system that enables patients who have reached a therapeutic impasse to benefit, on an exceptional and temporary basis, from certain drugs that are not authorized for a specific therapeutic indication. To this end, a certain amount of data (patient characteristics, treatment efficacy, quality of […]